PEP-Therapy’s lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment...

Radiopharm Theranostics presented data at EMIM 2025 demonstrating the effectiveness of RAD202, a HER2-targeting single domain antibody, for both...

Bitterroot Bio will present Phase 1 study results for BRB-002, a novel anti-CD47 therapy for atherosclerotic cardiovascular disease (ASCVD),...

Curevo Vaccine secured $110 million in Series B funding to advance the development of its shingles vaccine, amezosvatein. The...

NurExone Biologic Inc. has successfully completed a preclinical study of its ExoPTEN treatment for spinal cord injuries, demonstrating significant...

Gradalis, a clinical-stage biotech company, published a peer-reviewed article in Scientific Reports detailing their novel exome sequencing procedure and...

Korro Bio announced that its investigational medicine, KRRO-110, received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin...

Gain Therapeutics has dosed the first Parkinson’s disease patient in a Phase 1b clinical trial of its lead candidate,...

Eton Pharmaceuticals announced positive results from a bioequivalence study of ET-600, its patented oral solution of desmopressin for central...

ANI Pharmaceuticals received FDA approval for an expanded label for ILUVIEN, adding chronic non-infectious uveitis affecting the posterior segment...